Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Financing Activities (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Cash from Financing Activities for 16 consecutive years, with $122000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 100.82% to $122000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $216000.0 through Dec 2025, up 100.2% year-over-year, with the annual reading at $216000.0 for FY2025, 100.2% up from the prior year.
  • Cash from Financing Activities hit $122000.0 in Q4 2025 for Ironwood Pharmaceuticals, up from $88000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $399.1 million in Q2 2023 to a low of -$150.3 million in Q2 2022.
  • Historically, Cash from Financing Activities has averaged -$3.8 million across 5 years, with a median of $6000.0 in 2025.
  • Biggest five-year swings in Cash from Financing Activities: soared 820.0% in 2021 and later crashed 9508.78% in 2023.
  • Year by year, Cash from Financing Activities stood at -$18.6 million in 2021, then soared by 115.1% to $2.8 million in 2022, then plummeted by 1914.11% to -$50.9 million in 2023, then skyrocketed by 70.75% to -$14.9 million in 2024, then skyrocketed by 100.82% to $122000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for IRWD at $122000.0 in Q4 2025, $88000.0 in Q2 2025, and $6000.0 in Q1 2025.